Metagenomi Therapeutics, Inc.
MGX
$1.16
-$0.01-0.86%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -103.02% | -69.76% | -59.32% | -24.80% | -57.45% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -103.02% | -69.76% | -59.32% | -24.80% | -57.45% |
| Cost of Revenue | 0.02% | -23.24% | -7.18% | -3.71% | -20.53% |
| Gross Profit | -62.71% | 14.10% | -29.82% | -12.77% | -68.36% |
| SG&A Expenses | -14.14% | -3.97% | -4.18% | -18.66% | -18.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.34% | -19.13% | -6.48% | -7.08% | -19.99% |
| Operating Income | -37.10% | 11.62% | -18.15% | -2.04% | -24.46% |
| Income Before Tax | -38.35% | 7.59% | 8.58% | 1.21% | -53.53% |
| Income Tax Expenses | -- | -89.80% | 102.81% | 88.89% | 102.00% |
| Earnings from Continuing Operations | -38.05% | 7.91% | 3.72% | -8.63% | -85.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -38.05% | 7.91% | 3.72% | -8.63% | -85.38% |
| EBIT | -37.10% | 11.62% | -18.15% | -2.04% | -24.46% |
| EBITDA | -39.98% | 11.90% | -20.38% | -2.36% | -26.35% |
| EPS Basic | -36.21% | 9.28% | 4.16% | -6.93% | -82.74% |
| Normalized Basic EPS | -46.00% | 8.98% | -28.11% | -7.88% | -41.49% |
| EPS Diluted | -36.21% | 9.28% | 4.16% | -6.93% | -82.74% |
| Normalized Diluted EPS | -46.00% | 8.98% | -28.11% | -7.88% | -41.49% |
| Average Basic Shares Outstanding | 1.35% | 1.52% | 0.45% | 1.59% | 1.45% |
| Average Diluted Shares Outstanding | 1.35% | 1.52% | 0.45% | 1.59% | 1.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |